| Biomarker ID | 921 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation Status Of A0X1; CYBA; EDG3; ELF4; EPB41L3; FLJ12056; FLJ90650; FLT4; GAS6; GRASP; GSTP1; HAAO; HIF3A; HOXC11; LEP; MGC39606; MOBKL2B; RAB34; RARb; RHCG; RND2; SLC34A2; SPATA6; TPM4; ZNF154 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Methylated in PCA: |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Tumor Vs Normal Tissues |
| Type of Biomarker | Diagnostic |
| Cohort | 4 different sub groups of patients with prostate cancer: (i) tumor versus matched normal tissues ((ii) recurrence versus nonrecurrence (iii) clinical versus biochemical recurrence and (iv) systemic recurrence versus local recurrence. 20 patients from each group were taken |
| Senstivity | HIF3A(90.0); HAAO(89.4); RARb(84.2); GSTP1(94.7) |
| Specificity | HIF3A(100); HAAO(100); RARb(100); GSTP1(100) |
| AUC | HIF3A(0.932); HAAO(0.947); RARb(0.912); GSTP1(0.977) |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | Pyrosequencing |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | A0X1, CYBA, EDG3, ELF4, EPB41L3, FLJ12056, FLJ90650, FLT4, GAS6, GRASP, GSTP1, HAAO, HIF3A, HOXC11, LEP, MGC39606, MOBKL2B, RAB34, RARb, RHCG, RND2, SLC34A2, SPATA6, TPM4, ZNF154 |